GlobalData on MSN7h
Sanofi increases ownership stake partaking in pharma buyback trendJust days after taking back some of the stake held by L’Oréal, Sanofi has agreed to repurchase its own shares worth €2bn ...
According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...
Sanofi, AstraZeneca and two leading trade groups want clarity around an appellate decision that called for Teva to delist ...
Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...
The deal will diversify the French beauty giant’s funding sources at a time when the industry is undergoing a slowdown.
Sanofi-Aventis US LLC filed a lawsuit against the Department of Health and Human Services (HHS) and the Health Resources and ...
While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...
AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company ...
Sanofi (NASDAQ:SNY) has executed the first tranche of its €5 billion stock buyback program. A first tranche of this program was announced on February 3, 2025, and executed on February 5, 2025, for an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback